Literature review evaluates biopsy safety and cancer detection rates using Tru-CoreTM URO, suggesting effectiveness across approaches.
Objective:To evaluate the safety and efficacy of the Tru-CoreTM URO automatic biopsy device(Argon Medical, formerly Angiotech) for prostate biopsies via trans perineal and trans rectalapproaches, synthesizing clinical studies that have utilized this device.Methods: A literature review was performed to identify clinical studies explicitly using the Tru-CoreTM URO (18-gauge automated core biopsy instrument) in prostate cancer diagnosis.Key outcomes extracted included total number of biopsies, overall cancer detection rates(with Gleason grade/ISUP risk stratification when available), and biopsy-related complications(hematuria, rectal bleeding, infection/sepsis, urinary retention, etc.). Data wereaggregated separately for transrectal ultrasound (TRUS)-guided and trans-perineal biopsyapproaches.
No takes yet. Share an insight, caveat, or question.
Stibbs et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: